CASIF (CASI Pharmaceuticals) Accounts Payable & Accrued Expense: $26.12 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASIF CASI Pharmaceuticals Inc CASIF
24 GF Score
Price $0.15
GF Value $1.08
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Accounts Payable & Accrued Expense?

CASI Pharmaceuticals CASIF 24 Accounts Payable & Accrued Expense is $26.12 Mil as of Jun. 2026. GuruFocus rates CASIF with a GF Score™ of 24/100 and a GF Value™ of $1.08 (Possible Value Trap). The stock has 5 warning signs investors should review.

CASI Pharmaceuticals's quarterly accounts payable & accrued expense increased from Sep. 2025 ($20.57 Mil) to Dec. 2025 ($21.04 Mil) and increased from Dec. 2025 ($21.04 Mil) to Jun. 2026 ($26.12 Mil).

CASI Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2023 ($13.46 Mil) to Dec. 2024 ($14.37 Mil) and increased from Dec. 2024 ($14.37 Mil) to Dec. 2025 ($21.04 Mil).

CASI Pharmaceuticals Accounts Payable & Accrued Expense Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Accounts Payable & Accrued Expense Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable & Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.61 13.52 13.46 14.37 21.04

CASI Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Jun26
Accounts Payable & Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.22 19.00 20.57 21.04 26.12
CASIF
24GF Score
CASI Pharmaceuticals Inc CASIF
Accounts Payable & Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

What does a Accounts Payable & Accrued Expense of $26.12 Mil mean?
CASI Pharmaceuticals (CASIF) has a Accounts Payable & Accrued Expense of $26.12 Mil as of Jun. 2026. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on CASI Pharmaceuticals and its competitors.
Is CASI Pharmaceuticals' Accounts Payable & Accrued Expense too high?
CASI Pharmaceuticals' current Accounts Payable & Accrued Expense is $26.12 Mil. Overall, CASI Pharmaceuticals has a GF Score™ of 24/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Accounts Payable & Accrued Expense compare to CMND and VBIO?
CASI Pharmaceuticals' Accounts Payable & Accrued Expense of $26.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable & Accrued Expense for a Biotechnology company?
A good Accounts Payable & Accrued Expense depends on the Biotechnology industry context. However, Accounts Payable & Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable & Accrued Expense mean?
A high Accounts Payable & Accrued Expense can signal that a stock is expensive relative to its fundamentals. Accounts payable and accrued expenses are amounts a company expects to pay to suppliers and others. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Accounts Payable & Accrued Expense is $26.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CASI Pharmaceuticals (CASIF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.08, compared to a current price of $0.15 — trading 85.8% below its estimated fair value. The current Accounts Payable & Accrued Expense is $26.12 Mil. CASI Pharmaceuticals' overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable & Accrued Expense calculated?
Accounts Payable & Accrued Expense is calculated from a company's financial statements. For CASI Pharmaceuticals (CASIF), the current Accounts Payable & Accrued Expense is $26.12 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of $0.15 is trading 85.8% below its estimated GF Value™ of $1.08. GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CASIF:

  • Accounts Payable & Accrued Expense: $26.12 Mil
  • GF Value™: $1.08 vs. price of $0.15 (85.8% below fair value)
  • GF Score™: 24/100 with 5 warning signs

No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
24GF Score

Get the complete analysis for CASIF

Accounts Payable & Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$1.08
GF Value